JP2015534573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534573A5 JP2015534573A5 JP2015536136A JP2015536136A JP2015534573A5 JP 2015534573 A5 JP2015534573 A5 JP 2015534573A5 JP 2015536136 A JP2015536136 A JP 2015536136A JP 2015536136 A JP2015536136 A JP 2015536136A JP 2015534573 A5 JP2015534573 A5 JP 2015534573A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- active site
- carbamimidoyl
- benzimidazol
- sulfamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 11
- 108010054265 Factor VIIa Proteins 0.000 claims 8
- 229940012414 factor viia Drugs 0.000 claims 8
- 239000003381 stabilizer Substances 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 102100023804 Coagulation factor VII Human genes 0.000 claims 6
- 108010023321 Factor VII Proteins 0.000 claims 6
- 229940012413 factor vii Drugs 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000001384 succinic acid Substances 0.000 claims 4
- -1 5-carbamimidoyl-1H-benzimidazol-2-yl Chemical group 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- WDJHHCAKBRKCLW-IBGZPJMESA-N (2S)-2-[[2-[3-(6-carbamimidoyl-1H-benzimidazol-2-yl)-4-hydroxy-5-(2-hydroxy-5-sulfamoylphenyl)phenyl]acetyl]amino]butanedioic acid Chemical compound N=1C2=CC(C(=N)N)=CC=C2NC=1C(C=1O)=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=CC=1C1=CC(S(N)(=O)=O)=CC=C1O WDJHHCAKBRKCLW-IBGZPJMESA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- WDJHHCAKBRKCLW-LJQANCHMSA-N (2R)-2-[[2-[3-(6-carbamimidoyl-1H-benzimidazol-2-yl)-4-hydroxy-5-(2-hydroxy-5-sulfamoylphenyl)phenyl]acetyl]amino]butanedioic acid Chemical compound N=1C2=CC(C(=N)N)=CC=C2NC=1C(C=1O)=CC(CC(=O)N[C@H](CC(O)=O)C(O)=O)=CC=1C1=CC(S(N)(=O)=O)=CC=C1O WDJHHCAKBRKCLW-LJQANCHMSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 239000011261 inert gas Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712187P | 2012-10-10 | 2012-10-10 | |
| US61/712,187 | 2012-10-10 | ||
| US201361790957P | 2013-03-15 | 2013-03-15 | |
| US61/790,957 | 2013-03-15 | ||
| EP13159833.6 | 2013-03-18 | ||
| EP13159833 | 2013-03-18 | ||
| PCT/EP2013/071225 WO2014057069A1 (en) | 2012-10-10 | 2013-10-10 | Liquid pharmaceutical composition of factor vii polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015534573A JP2015534573A (ja) | 2015-12-03 |
| JP2015534573A5 true JP2015534573A5 (enExample) | 2016-12-01 |
Family
ID=47901828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536136A Withdrawn JP2015534573A (ja) | 2012-10-10 | 2013-10-10 | 第ｖｉｉ因子ポリペプチドの液体医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150273027A1 (enExample) |
| EP (1) | EP2906236A1 (enExample) |
| JP (1) | JP2015534573A (enExample) |
| CN (1) | CN104717973A (enExample) |
| WO (2) | WO2014057069A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016029214A1 (en) * | 2014-08-22 | 2016-02-25 | Biocryst Pharmaceuticals, Inc. | Compositions and uses of amidine derivatives |
| CN117964683A (zh) | 2018-05-29 | 2024-05-03 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| US12110288B2 (en) | 2019-12-04 | 2024-10-08 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| CA3159159A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| JP4451514B2 (ja) | 1999-08-24 | 2010-04-14 | 財団法人化学及血清療法研究所 | 血液凝固第ｖｉｉ因子改変体 |
| AU2001254624A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Human coagulation factor vii variants |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| EP1319067A2 (en) | 2000-09-13 | 2003-06-18 | Novo Nordisk A/S | Human coagulation factor vii variants |
| AU2001291653A1 (en) | 2000-10-02 | 2002-04-15 | Novo-Nordisk A/S | Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| US7173000B2 (en) | 2000-11-09 | 2007-02-06 | The Scripps Research Institute | Modified factor VIIa |
| WO2002077218A1 (en) | 2001-03-22 | 2002-10-03 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| CA2452391A1 (en) * | 2001-07-09 | 2003-01-23 | Axys Pharmaceuticals, Inc. | 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors |
| JP4537059B2 (ja) | 2001-09-27 | 2010-09-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| JP2005512524A (ja) | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| EP1569912B1 (en) | 2002-12-03 | 2015-04-29 | Pharmacyclics, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| ES2339393T3 (es) | 2002-09-25 | 2010-05-19 | Novo Nordisk Health Care Ag | Polipeptidos del factor de coagulacion humano vii. |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| RU2388460C2 (ru) | 2003-08-14 | 2010-05-10 | Ново Нордиск Хелс Кеа Аг | Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii |
| WO2005024006A2 (en) | 2003-09-09 | 2005-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
| JP2008501700A (ja) * | 2004-06-02 | 2008-01-24 | ファーマサイクリックス，インコーポレイティド | 第ＶＩＩａ因子阻害剤 |
| JP2008531525A (ja) * | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| TW201206905A (en) | 2010-05-20 | 2012-02-16 | Eisai R & Amp D Man Co Ltd | Prodrug of triazolone compound |
-
2013
- 2013-10-10 EP EP13776782.8A patent/EP2906236A1/en not_active Withdrawn
- 2013-10-10 WO PCT/EP2013/071225 patent/WO2014057069A1/en not_active Ceased
- 2013-10-10 US US14/434,510 patent/US20150273027A1/en not_active Abandoned
- 2013-10-10 JP JP2015536136A patent/JP2015534573A/ja not_active Withdrawn
- 2013-10-10 CN CN201380052853.3A patent/CN104717973A/zh not_active Withdrawn
- 2013-10-10 WO PCT/EP2013/071224 patent/WO2014057068A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534573A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| PH12017500844B1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| EA201492021A1 (ru) | Антительный состав | |
| JP2016503762A5 (enExample) | ||
| JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
| JP2011513492A5 (enExample) | ||
| JP2016503058A5 (enExample) | ||
| CN110638752A (zh) | 注射剂 | |
| RU2016147362A (ru) | Препараты жидкого концетрата циклофосфамида | |
| BR112012008666A2 (pt) | processo para a preparação de um pó, formulação, e, uso do pó preparado por um processo | |
| KR20190092481A (ko) | 은 및 셀레늄을 포함하는 항생제 조성물 | |
| RU2009119912A (ru) | Аминные производные и их применение в бета-2-адренорецептор-опосредованных заболеваний | |
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP6501399B2 (ja) | ペメトレキセドを含有する注射用溶液製剤 | |
| DK2018153T3 (da) | Flydende orale sammensætninger | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia | |
| RU2014115289A (ru) | Композиция пазопаниба | |
| WO2016024369A1 (ja) | がん治療用医薬組成物 | |
| JP2010105965A (ja) | バンコマイシン製剤 | |
| JP2013227300A (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| EA024344B1 (ru) | Составы для инфузии лантибиотиков типа b | |
| CA2520813A1 (en) | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists | |
| TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. |